US 12,215,130 B2
Cytokine-albumin binding moiety fusion proteins and uses thereof
Ziyang Zhong, Belmont, CA (US); Fan Ye, Mountain View, CA (US); Matthew Siegel, Menlo Park, CA (US); Jianing Huang, San Mateo, CA (US); Eric Liao, San Francisco, CA (US); and Ella Li, San Francisco, CA (US)
Assigned to ANWITA BIOSCIENCES, INC., San Carlos, CA (US)
Appl. No. 17/253,481
Filed by Anwita Biosciences, Inc., San Carlos, CA (US)
PCT Filed Jun. 17, 2019, PCT No. PCT/US2019/037558
§ 371(c)(1), (2) Date Dec. 17, 2020,
PCT Pub. No. WO2019/246004, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/809,496, filed on Feb. 22, 2019.
Claims priority of provisional application 62/686,481, filed on Jun. 18, 2018.
Prior Publication US 2021/0230242 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/765 (2006.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/54 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/765 (2013.01); C07K 16/30 (2013.01); C07K 16/44 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A fusion protein comprising: a) an IL-21 and b) an albumin binding moiety that is a single domain antibody (sdAb) comprising:
(1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 69;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 70; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 71;
(2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 72;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 73; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 74;
(3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 75;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 76; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 77;
(4) a CDR1 comprising the amino acid sequence of SEQ ID NO: 78;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 79; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 80;
(5) a CDR1 comprising the amino acid sequence of SEQ ID NO: 81;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 82; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 83;
(6) a CDR1 comprising the amino acid sequence of SEQ ID NO: 84;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 85; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 86;
(7) a CDR1 comprising the amino acid sequence of SEQ ID NO: 87;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 88; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 89;
(8) a CDR1 comprising the amino acid sequence of SEQ ID NO: 90;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 91; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 92; or
(9) a CDR1 comprising the amino acid sequence of SEQ ID NO: 93;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 94; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 95.